Viridian Therapeutics, Inc. (FRA:1S1)

Market Cap	2.58B
Revenue (ttm)	60.33M
Net Income (ttm)	-209.08M
Shares Out	n/a
EPS (ttm)	-2.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55
Average Volume	2
Open	27.68
Previous Close	27.01
Day's Range	27.68 - 27.68
52-Week Range	9.60 - 27.68
Beta	n/a
RSI	75.68
Earnings Date	Feb 27, 2026

About Viridian Therapeutics

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of e...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 143
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1S1

Financial Performance

In 2024, Viridian Therapeutics's revenue was $302,000, a decrease of -3.82% compared to the previous year's $314,000. Losses were -$208.56 million, 19.2% more than in 2023.

Financial numbers in USD